Blood amyloid β oligomerization as a biomarker of Alzheimer’s disease: a blinded validation study
Abstract INTRODUCTION: Oligomeric amyloid ß (Aß) is one of the major contributors to the pathomechanism of AD; Aß oligomerization in plasma can be measured using a Multimer Detection System-Oligomeric Aß (MDS-OAß) after incubation with spiked synthetic Aß. METHODS: We evaluated the clinical sensitivity and specificity of the MDS-OAß values by inBlood TM OAß test using heparin-treated plasma samples from 52 AD patients in comparison with 52 community-based subjects with normal cognition (NC). The inclusion criterion was proposed by the NINCDS-ADRDA and additionally required for the least 6 months of follow-up from the initial clinical diagnosis in the course of AD. RESULTS: The MDS-OAβ values were 1.43 ± 0.30 ng/ml in AD and 0.45 ± 0.19 ( p <0.001) in NC, respectively. Using a cut-off value of 0.78 ng/ml, the results revealed that 100% sensitivity 92.31% specificity. DISCUSSION: MDS-OAß to measure plasma Aβ oligomerization is a valuable blood-based biomarker for clinical diagnosis of AD, with high sensitivity and specificity..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
ResearchSquare.com - (2020) vom: 27. Apr. Zur Gesamtaufnahme - year:2020 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Youn, Young Chul [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.21203/rs.2.19960/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA034647988 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA034647988 | ||
| 003 | DE-627 | ||
| 005 | 20230429184826.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220113s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.2.19960/v1 |2 doi | |
| 035 | |a (DE-627)XRA034647988 | ||
| 035 | |a (ResearchSquare)10.21203/rs.2.19960/v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Youn, Young Chul |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Blood amyloid β oligomerization as a biomarker of Alzheimer’s disease: a blinded validation study |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract INTRODUCTION: Oligomeric amyloid ß (Aß) is one of the major contributors to the pathomechanism of AD; Aß oligomerization in plasma can be measured using a Multimer Detection System-Oligomeric Aß (MDS-OAß) after incubation with spiked synthetic Aß. METHODS: We evaluated the clinical sensitivity and specificity of the MDS-OAß values by inBlood TM OAß test using heparin-treated plasma samples from 52 AD patients in comparison with 52 community-based subjects with normal cognition (NC). The inclusion criterion was proposed by the NINCDS-ADRDA and additionally required for the least 6 months of follow-up from the initial clinical diagnosis in the course of AD. RESULTS: The MDS-OAβ values were 1.43 ± 0.30 ng/ml in AD and 0.45 ± 0.19 ( p <0.001) in NC, respectively. Using a cut-off value of 0.78 ng/ml, the results revealed that 100% sensitivity 92.31% specificity. DISCUSSION: MDS-OAß to measure plasma Aβ oligomerization is a valuable blood-based biomarker for clinical diagnosis of AD, with high sensitivity and specificity. | ||
| 700 | 1 | |a Lee, Byoung Sub |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Gwang Je |e verfasserin |4 aut | |
| 700 | 1 | |a Ryu, Ji Sun |e verfasserin |4 aut | |
| 700 | 1 | |a Lim, Kuntaek |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Ryan |e verfasserin |4 aut | |
| 700 | 1 | |a Suh, Jeewon |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Young Ho |e verfasserin |4 aut | |
| 700 | 1 | |a Pyun, Jung-Min |e verfasserin |4 aut | |
| 700 | 1 | |a Ryu, Nayoung |e verfasserin |4 aut | |
| 700 | 1 | |a Kang, Min Ju |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Hye Ryoun |e verfasserin |4 aut | |
| 700 | 1 | |a Kang, Sungmin |e verfasserin |4 aut | |
| 700 | 1 | |a An, Seong Soo A. |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, SangYun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2020) vom: 27. Apr. |
| 773 | 1 | 8 | |g year:2020 |g day:27 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.2.19960/v1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2020 |b 27 |c 04 | ||
| 953 | |2 045F |a 570 | ||